Reply to: “Chemoradiotherapy in Pancreatic Cancer: Toward Precision Oncology,” “Key Methodological Considerations in the Interpretation of the CONKO-007 Trial,” and “Chemoradiotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer”

Rainer Fietkau

Sabine Semrau

Annett Kallies

Rainer Fietkau, MD, Sabine Semrau, MD, and Annett Kallies, PhD, Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany, National Center for Tumor Diseases (NCT), NCT WERA, a Partnership Between DKFZ, and the Universities and University Hospitals in Wurzburg, Erlangen, Germany; Werner Adler, PhD, Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen-Nurnberg, Erlangen, Germany, Helmut Oettle, MD, Department of Hematology, Oncology, and Tumor Immunology, Charité—Universitätsmedizin Berlin, Campus Charité Mitte, Berlin, Germany

Werner Adler

Rainer Fietkau, MD, Sabine Semrau, MD, and Annett Kallies, PhD, Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany, National Center for Tumor Diseases (NCT), NCT WERA, a Partnership Between DKFZ, and the Universities and University Hospitals in Wurzburg, Erlangen, Germany; Werner Adler, PhD, Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen-Nurnberg, Erlangen, Germany, Helmut Oettle, MD, Department of Hematology, Oncology, and Tumor Immunology, Charité—Universitätsmedizin Berlin, Campus Charité Mitte, Berlin, Germany

Helmut Oettle

Rainer Fietkau, MD, Sabine Semrau, MD, and Annett Kallies, PhD, Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany, National Center for Tumor Diseases (NCT), NCT WERA, a Partnership Between DKFZ, and the Universities and University Hospitals in Wurzburg, Erlangen, Germany; Werner Adler, PhD, Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen-Nurnberg, Erlangen, Germany, Helmut Oettle, MD, Department of Hematology, Oncology, and Tumor Immunology, Charité—Universitätsmedizin Berlin, Campus Charité Mitte, Berlin, Germany